Theodore Hobart Welling MD

General Surgery•La Jolla, CA

Hepatobiliary Surgery, Pancreas

Professor, Surgery, UC San Diego Health

Join to View Full Profile

3855 Health Sciences DrLa Jolla, CA 92093
Phone+1 800-926-8273
Fax+1 212-731-6017

Summary

During residency, I was drawn to the specialty of hepatobiliary and pancreatic oncology—the treatment of cancers that affect the liver, gallbladder, bile ducts, and pancreas—and liver transplantation, which led me to pursue a fellowship in transplantation. I chose to focus specifically on hepatobiliary and pancreatic surgery, and today, my interest in hepatobiliary and pancreatic oncology clinical care and research continues to grow.

As director of the Liver Tumor Program, my aim is to establish a multidisciplinary approach to treating people who have liver cancer. Together, we are a team of hepatobiliary surgeons, gastrointestinal medical oncologists, hepatologists, interventional radiologists, radiation oncologists, and nurses, who collaborate to provide the highest level of care. We manage cancers that originate in the liver and bile ducts, as well as cancers that spread to the liver.

I also participate in a multidisciplinary pancreatic cancer program. We develop innovative strategies to allow more patients to ultimately undergo surgical resection.

I conduct translational research and clinical research that is primarily focused on liver cancer. I also collaborate with other researchers to identify new areas of biology to target therapeutically and ways to optimize existing therapies. The results of our recent study led to FDA approval for nivolumab, a targeted drug that shrinks liver tumors or slows their growth by activating the immune system.

I am a member of the ACS, ILCA, ASCO, ASTS, AASLD, and AHPBA.

Education & Training

University of Michigan Health SystemFellowship, Abdominal Transplant Surgery, 2005 - 2007
University of MichiganResidency, Surgery, 1999 - 2005
University of Michigan Medical SchoolClass of 1999
University of Michigan RackhamMasters, 1992 - 1994
University of Michigan Medical SchoolB.S., Biology, 1987 - 1991

Certifications & Licensure

CA State Medical License 2024 - 2026
NY State Medical License 2017 - 2025
MI State Medical License 1999 - 2018
American Board of Surgery Surgery

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Translational Research Award Society of University Surgeons, 2010
Finalist, AAS Joel J. Roslyn Faculty Research Award 2009
Young Investigator Award American Society of Transplantation, 2004
Research Award/Fellowship National Kidney Foundation, 2002
Bronze Beeper Medical Student Teaching Award 2000
Alpha Omega Alpha Medical Honor Society 1999
National Research Fellowship American College of Rheumatology, 1996
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Intraoperative Glucose Control in Liver Transplant Start of enrollment: 2008 Jul 01
Completed
Phase 4
Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) Start of enrollment: 2017 Jul 01
Withdrawn
Phase 1, Phase 2
Nivolumab Combined With BMS-986253 in HCC Patients Start of enrollment: 2019 Sep 12
COMPLETED
PHASE2
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Start of enrollment: 2021 Oct 29
RECRUITING
Join now to see all

Publications & Presentations

PubMed

1 citations
Longitudinal assessment of disparities in pancreatic cancer care: A retrospective analysis of the National Cancer Database.
Mahip Grewal, Victor J Kroon, Sarah R Kaslow, Anthony M Sorrentino, Megan D Winner
World Journal of Surgery. 2025-01-01
2 citations
Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Registry Study.
Robert C G Martin 2nd, Rebekah Ruth White, Malcolm M Bilimoria, Michael D Kluger, David A Iannitti
Cancers. 2024-11-21
5 citations
Progression of Site-specific Recurrence of Pancreatic Cancer and Implications for Treatment.
Ingmar F Rompen, Jonah Levine, Joseph R Habib, Elisabetta Sereni, Nabiha Mughal
Annals of Surgery. 2024-08-01

Journal Articles

Comprehensive and integrative genomic characterization of hepatocellular carcinoma
The Cancer Genome Atlas Research Network, Cell, 1/1/2017
Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: A phase 2 clinical trial
Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, Parikh ND, Welling TH, Normolle D, Ten Haken RK, Lawrence TS, JAMA Oncol, 1/1/2017
Non-invasive liver ablation using histotripsy: preclinical safety study in an in vivo porcine model
Vlaisavljevich, E, Gabe O, Lundt M, Teofilovic D, Ives K, Duryea A, Bertolina J, Welling TH, Zhen X, Ultrasound Med Biol, 1/1/2017
Nivolumab in patients with advanced hepatocellular carcinoma (Checkmate 040): results of phase 1/2 dose escalation and expansion
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim T, Choo S, Trojan J, Welling TH, Meyer T, Kang Y, Yeo W, Chopra A, Anderson J, dela Cruz C, Lang L, Ne..., The Lancet, 1/1/2017
GM-CSF mediates mesenchymal-epithelial crosstalk in pancreatic cancer
Waghray M, Yalamanchili M, Dziubinski M, Zeinali M, Erkkinen M, Yang H, Schradle KA, Welling TH, Palmbos PL, Abel EV, Sahai V, Nagrath S, Wong L, Simeone DM, Cancer Discov, 1/1/2016
Non-invasive ultrasound liver ablation using histotripsy: chronic study in an in vivo rodent model
Vlaisavljevich E, Gail T, Gail M, Greve JM, Cheng X, Ives K, Shi J, Lifang J, Ara A, Hall T, Welling TH, Gabe O, Roberts W, Zhen X, Ultrasound Med Biol, 1/1/2016
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, Wei S, Crespo J, Wan S, Vatan L, Szeliga W, Shao I, Wang Y, Liu Y, Varambally S, Chinnaiyan AM, Welling TH, Marquez VE, K..., Nat Immunol, 1/1/2016
Sensitivity of KRAS-mutant colorectal cancers to combination therapy that co-targets MEK and CDK4/6
Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold, JS, Clin Cancer Res, 1/1/2016
Myeloid cells in hepatocellular carcinoma
Wan S, Kuo N, Kryczek I, Zou W, and Welling TH, Hepatology, 1/1/2015
Internal biliary stenting during orthotopic liver transplantation: anastomotic complications, post-transplant biliary interventions, and survival
Mathur AK, Nadig SN, Kingman S, Lee D, Kincade K, Sonnenday CJ, Welling TH, Clin Transpl, 1/1/2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomized, double-blind, placebo-controlled trial
Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA..., Lancet Oncol, 1/1/2015
Heterogeneity of the CD90+ population in different stages of hepatocarcinogenesis
Smathorn T, Zhu J, Qixing L, Welling TH, Zhang M, Lubman DM, J Proteomics Bioinform, 1/1/2014
Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73)
Snider NT, Altshuler PJ, Wan S, Welling TH, Cavalcoli JD, Omary MB, Mol Biol Cell, 1/1/2014
Neoadjuvant stereotactic body radiation therapy (SBRT), capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma
Welling TH, Feng M, Wan S, Hwang, SY, Volk ML, Lawrence TS, Zalupski MM, Sonnenday CJ, Liver Transpl, 1/1/2014
CD4+ T lymphocytes ablation prevents pancreatic carcinogenesis in mice
Zhang Y, Yan W, Esha M, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, Pasca di Magliano, M, Cancer Immunol Res, 1/1/2014
T cells and co-stimulation in cancer
Maj T, Wei S, Welling TH, and Zou W, Cancer J, 1/1/2013
Elevated serum IL-8 is associated with presence of hepatocellular carcinoma and independently predicts survival
Welling TH, Fu S, Wan S, Zou W, and Marrero JA, Cancer Invest, 1/1/2012
The effect of smoking on biliary complications following liver transplantation
Mathur AK, Ranney DN, Patel SP, Lee DS, Bednar F, Lynch RJ, Welling TH, and Englesbe, MJ, Transplant Int, 1/1/2011
The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre
Singal AG, Rakoski M, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS, Marrero JA, Aliment Pharmacol Ther, 1/1/2010
Portal vein thrombosis and survival in patients with cirrhosis
Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling TH, Punch JD, Lynch RJ, Marrero JA, Pelletier SJ, Liver Transpl, 1/1/2010
Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/PD-1 interactions
Wu K, Kryczek I, Chen L, Zou W, Welling TH, Cancer Res., 1/1/2009
Modern Diagnosis and Management of Hepatocellular Carcinoma
Marrero JA, Welling TH, Clinics in Liver Dis, 1/1/2009
Phenotype, distribution, generation, functional and clinical relevance of Th17 cells in the human tumor environments
Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone DM, Welling TH, Chang A, Coukos G, Liu R, Zou W, Blood, 1/1/2009
FOXP3 defines regulatory T cells in human tumor and autoimmune disease
Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone DM, Redman B, Welling TH, Chang A, Zou W, Cancer Res., 1/1/2009
Role of liver transplantation in the treatment of cholangiocarcinoma
Singal A, Welling TH, Marrero JA, Expert Rev Anticancer Ther, 1/1/2009
Join now to see all

Books/Book Chapters

Operative Techniques in Transplantation Surgery
Chapter: "Hepatic Artery Reconstruction During Liver Transplantation."
Mathur AK and Welling THEditors: Englesbe MA and Mulholland MW.Wolters Kluwer Health2015
Developments in T Cell Based Cancer Immunotherapies
Chapter: "T Cell Fate in the Tumor Microenvironment."
Crespo J, Kryczek I, Welling T, Wei S, and Zou WEditors: Ascierto PA, Stroncek DF, and Wang E.Springer International Publishing2015
Greenfield's Surgery: Scientific Principles and Practice
Chapter: "Hepatic Transplantation."
Welling TH, Pelletier SJEditors: Mulholland MW, Lillemoe KD, Doherty GM, Simeone DS, and Upchurch GJ.Lippincott Williams & WilkinsEdition 5th,2011
Greenfield's Surgery: Scientific Principles and Practice
Chapter: "Hepatic Neoplasms."
Sonnenday CJ, Welling TH, Pelletier SJEditors: Mulholland MW, Lillemoe KD, Doherty GM, Simeone DS, and Upchurch GJ.Lippincott Williams & WilkinsEdition 5th,2011
Complications in Surgery
Chapter: "Complications of Hepatic Surgery"
Welling TH and Knol JAEditors: Mulholland MW and Doherty GA.ippincott Williams & WilkinsEdition 2nd,2011
Current Procedures: Surgery
Chapter: "Hepatectomy."
Welling THEditors: Minter RM and Doherty GM.McGraw-Hill2010
Textbook of Gastroenterology
Chapter: "Gallbladder and Biliary Tract: Anatomy and Structural Anomalies."
Welling TH and Simeone DMEditors: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, and Powell DW.Wiley-BlackwellEdition 5th,2009
Atlas of Gastroenterology
Chapter: "Gallbladder and Biliary Tract: Anatomy and Structural Anomalies."
Welling TH and Simeone DMEditors: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, and Powell DW.Wiley-BlackwellEdition 4th,2009
A Companion Manual to Current Surgical Diagnosis and Treatment
Chapter: "Hepatobiliary Diagnoses."
Welling THEditors: Doherty GM and Way LW.Lange/McGraw Hill Medical Publishing Division2005
Advances in Surgical Gene Therapy
Chapter: "Gene Therapy for Vascular Disease."
Messina LM, Welling TH, Sarkar R, Shanley CJ, Stanley JCEditors: Anderson DK.World Medical Communications Organizations Inc.1994
Join now to see all

Abstracts/Posters

Nivolumab in sorafenib-naive and-experienced patients with advanced hepatocellular carcinoma (HCC): survival, hepatic safety, and biomarker assessments in CheckMate 040.
Sangro B, Crocenzi TS, Yau T, Melero I, Welling TH, Kudo M, Hsu C, Trojan J, Kim T, Choo S, Meyer T, Kang Y, Yeo W, Chopra A, Baakili A, dela Cruz C, Lang L, Neely J, ..., American Association for the Study of Liver Diseases Annual Meeting, Presidential Plenary: Clinical Session, 1/23/2017
Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: Checkmate 040 study.
Sangro B, Yau T, Hsu C, Kudo M, Crocenzi TS, Choo S, Meyer T, Welling TH, Yeo W, Chopra A, Baakili A, dela Cruz C, Lang L, Neely J, Melero I, El-Khoueiry AB, and Trojan J, The International Liver Congress (EASL), Amsterdam, Netherlands, 1/21/2017
Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma: the checkmate 040 study.
Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi TS, Kim T, Choo S, Trojan J, Meyer T, Welling TH, Yeo W, Chopra A, Anderson J, Delacruz C, Lang L, Neely J, Tang H, ..., American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2017
Nivolumab in sorafenib-naive and –experienced patients with advanced hepatocellular carcinoma: CheckMate 040 study.
Crocenzi TS, El-Khoueiry AB, Yau T, Melero I, Sangro B, Kudo M, Hsu C, Trojan J, Kim T, Choo S, Meyer T, Kang Y, Yeo W, Chopra A, Baakili A, dela Cruz C, Lang L, Neely..., American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 1/5/2017
Nivolumab (Nivo) in patients (Pts) with advanced hepatocellular carcinoma (HCC): the checkmate 040 study.
Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi TS, Kim T, Choo S, Trojan J, Meyer T, Welling TH, Yeo W, Chopra A, Anderson J, Delacruz C, Lang L, Neely J, Tang H, ..., American Association for Study of Liver Diseases (AASLD), The Liver Meeting, Boston, MA, 1/11/2016
Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 checkmate 040 study.
Melero I, Sangro B, Yau T, Hsu C, Kudo M, Crocenzi TS, Kim T, Choo S, Trojan J, Meyer T, Welling TH, Yeo W, Chopra A, Anderson J, Delacruz C, Lang L, Neely J, Tang H, ..., European Society of Medical Oncology (ESMO), Copenhagen, Denmark, 1/1/2016
Phase 1/2 safety and anti-tumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the CheckMate-040 dose escalation study.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Welling TH, Yeo W, Chopra A, Anderson J, dela Cruz C, Lang L, Neely J, and Melero I, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 1/1/2016
Phase 1/2 safety and anti-tumor activity of nivolumab in patients with advanced hepatocellular carcinoma: CA209-040.
El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Yau T, Yeo W, Chopra A, Grosso JF, Lang L, Anderson J, dela Cruz C, and Sangro B, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 1/30/2015
Phase I dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular ca...
Sangro B, El-Khoueiry AB, Crocenzi TS, Welling TH, Feely W, Anderson J, Dela Cruz C, Melero I, EASL-The International Liver Conference, Vienna, Austria, 1/22/2015
Dual targeting of CDK4 and MEK as a combination treatment strategy for metastatic colorectal cancer.
Ziemke E, Dosch J, Shettigar A, Wan S, Welling T, Hardiman K, Sebolt-Leopold J, American Association of Cancer Research, 1/1/2014
Early experience with neoadjuvant stereotactic body radiation therapy (SBRT), capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma.
Welling TH, Feng M, Wan S, Hwang, SY, Volk ML, Lawrence TS, Zalupski MM, Sonnenday CJ, International Liver Cancer Association, Washington, DC, 1/1/2013
The morbidity of intraoperative biliary stenting following orthotopic liver transplantation.
Mathur AK, Nadig SN, Kingman S, Lee D, Kincade K, Sonnenday CJ, Welling TH, Americas Hepato-Pancreato-Biliary Association, Miami Beach, FL, 1/1/2013
"Phase 1 Dose Escalation Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC) with or without Chronic Vi...
Sangro B, Crocenzi TS, Welling TH, Iñarrairaegui M, Prieto J, Fuertes JC, Delanty L, Feely W, Anderson J, Grasela DM, Wigginton JM, Gupta AK, and Melero I, American Society of Clinical Oncology (ASCO), Chicago, IL, 1/1/2013
A Phase II Trial of Individualized Adaptive Stereotactic Body Radiotherapy (SBRT) for Patients at High Risk for Liver Damage.
Feng MU, Schipper MJ, Balter JM, Matuszak MM, Hadley SW, Welling TH, Volk ML, Pan C, Ben-Josef E, and Lawrence TS, American Society for Radiation Oncology (ASTRO), Atlanta, GA, 1/1/2013
Hepatocellular carcinoma tumor associated macrophages promote tumor stem cell function using IL-6 mediated signaling.
Wan S, Vatan L, Kryczek I, Sadovskaya A, Marrero JA, Zou W, Welling TH, International Liver Cancer Association, Berlin, Germany, 1/1/2012
Immune cells promote hepatocellular carcinoma stemness phenotype.
Wan S, Vatan L, Simeone DM, Kryczek I, Zou W, Welling TH, American Association of Cancer Research, Chicago, IL, 1/1/2012
Resistance of CD44+ hepatocellular carcinoma cancer stem cells to immune effector responses.
Wan S, Vatan L, Simeone DM, Kryczek I, Zou W, Welling TH, American Association of Cancer Research, Orlando, FL, 1/1/2011
miR-199a-3p targets CD44 positive hepatocellular carcinoma cell lines.
Henry JC, Park J, Jiang J, Kim JH, Roberts LR, Nagorney DM, Banerjee S, Welling TH, Schmittgen TD, American Association of Cancer Research, Orlando, FL, 1/1/2011
Hepatocellular carcinoma cancer stem cells demonstrate enhanced resistance to chemotherapy and evidence of an immunosuppressive environment.
Welling TH, Wan S, Vatan L, Kryczek I, Marrero JA, Zou W, International Liver Cancer Association, Montreal, Canada, 1/1/2010
Kupffer Cell Suppression of Intratumoral T Cell Effector Responses is Mediated By B7-H1 and PD-1 Interactions in Human Hepatocellular Carcinoma (HCC).
Welling TH, Wu K, Kryczek I, Marrero JM, Zou W, International Liver Cancer Association, Milan, Italy, 1/1/2009
Obesity and its impact on cancer-specific outcomes following liver resection.
Mathur AK, Sell K, Englesbe MJ, Sonnenday CJ, and Welling TH, Americas Hepato-Pancreato-Biliary Association (AHPBA), Miami Beach, FL, 1/1/2009
Antigen Presenting Cell B7-H1 and T Cell PD-1 are increased in human Hepatocellular Carcinoma: Evidence for increased immune regulation.
Welling TH, Wu K, Kryczek I, Zou W, 4th American Surgical Congress, 1/1/2009
The Effect of Locoregional Therapy for Hepatocellular Carcinoma prior to Liver Transplantation.
Mobley C, Welling TH, Sonnenday CJ, Englesbe MJ, Marrero JA, Pelletier SJ, American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, 1/1/2008
Are Patients with Portal Vein Thrombosis High-Risk Liver Transplant Candidates?
Englesbe MJ, Muhammad W, Ranney D, Al-Holou S, Kubus J, Sonnenday CJ, Welling TH, Punch JD, Pelletier SJ, ASTS 8th Annual State of the Art Winter Symposium, Marco Island, FL, 1/1/2008
Basiliximab induction increases postoperative infection rates with no change in HCV recurrence in liver transplant patients at risk for renal insufficiency.
Heidt DG, Ammori JB, Englesbe MJ, Sonnenday CJ, Pelletier SJ, and Welling TH, ASTS 8th Annual State of the Art Winter Symposium, Marco Island, FL, 1/1/2008
Join now to see all

Lectures

A phase II, randomized, controlled trial of nivolumab in combination with BMS-986253 or cabiralizumab in advanced hepatocellular carcinoma (HCC) patients.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
"Surgical Treatment of Hepatocellular Carcinoma"
Princeton Pike, NJ - 1/12/2017
"Tumor Associated Macrophages and Hepatocellular Carcinoma Progression"
University of Michigan - 1/21/2016
"Surgical Treatment for Hepatocellular Carcinoma"
New York, NY - 1/9/2016
"Biliary Neoplasms"
University of Michigan - 1/4/2016
"Translational Insights from the Hepatocellular Carcinoma Microenvironment: TAMs and Tumor Progression"
University of Michigan - 1/30/2015
"Hepatocellular Carcinoma Tumor Microenvironment and Cancer Stem Cells"
Portland, OR - 1/22/2015
"HCC-Who not to transplant-that's the question"
Miami, FL - 1/15/2015
"Indications and Outcomes with Liver Transplantation for Hepatocellular Carcinoma"
Novi, MI - 1/8/2015
"Benign Liver Lesions"
University of Michigan - 1/17/2014
"Surgical Management of Hepatobiliary Malignancy: A Multidisciplinary Approach"
West Michigan Cancer Center, Kalamazoo, MI - 1/16/2014
"Tumor Microenvironment and Human Hepatocellular Carcinoma Stem Cell Function"
Lansing, MI - 1/11/2014
"Recent Insights from the HCC Microenvironment"
University of Michigan - 1/2/2014
"Surgical Management of Hepatocellular Carcinoma"
University of Michigan - 1/18/2013
"Update on Hilar Cholangiocarcinoma: Neoadjuvant Therapy and Liver Transplantation"
University of Michigan - 1/10/2013
"Insights into Novel Therapies from the HCC Immune Microenvironment"
University of Michigan - 1/2/2013
"Patient Selection for Resection of Liver of Liver Metastases"
University of Michigan - 1/26/2012
"Evaluation and Management of Hepatocellular Carcinoma"
University of Michigan - 1/19/2012
"Primary Liver Neoplasms"
University of Michigan - 1/16/2012
"Resection and Transplantation for Hepatocellular Carcinoma"
Grand Rapids, MI - 1/13/2012
"Hepatocellular Carcinoma: Insights into Novel Therapies from the Immune Microenvironment"
Stellenbosch, South Africa - 1/12/2012
"Role of Resection and Transplantation in Management of Hepatocellular Carcinoma"
Saginaw, MI - 1/4/2012
"PD-1/PD-1L Pathway Blockade in Chronic Hepatitis B and Hepatocellular Carcinoma"
Newark, NJ - 1/25/2011
"Patient Selection for Resection of Liver Metastases"
Crystal Mountain Resort, Thompsonville, MI - 1/18/2011
"Hepatocellular Carcinoma Stem Cells and Microenvironmental Influence of Immune Cell Subsets"
1/18/2011
Join now to see all